Circumvention of cytarabine (Ara-C) resistance by 2-chloro-deoxyadenosine (2-CdA) in pediatric acute myeloid (AML) and acute lymphoblastic (ALL) leukemia: An in vitro study.

被引：0
|
作者：
Zwaan, CM
Kaspers, GJL
Pieters, R
Huismans, DR
Van Wering, ER
Janka-Schaub, GE
Creutzig, U
Henze, G
Veerman, AJP
机构：
[1] Vrije Univ Amsterdam, Univ Hosp Amsterdam, Dept Pediat Hematol Oncol, Amsterdam, Netherlands
[2] Sophia Childrens Hosp, Dept Hematol Oncol, Rotterdam, Netherlands
[3] Dutch Childhood Leukemia Study Grp, The Hague, Netherlands
[4] CoALL Study Grp, Hamburg, Germany
[5] AML BFM Study Grp, Munster, Germany
[6] BFM ALL Relapse Study Grp, Berlin, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1327
引用
收藏
页码：307A / 307A
页数：1
相关论文
共 50 条
  • [41] Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ≤ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MOS).
    Faderl, S
    Gandhi, V
    Giles, F
    Estey, E
    Garcia-Manero, G
    O'Brien, S
    Wierda, W
    Kwari, M
    Craig, A
    Kantarjian, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 584S - 584S
  • [42] CONCORDANT CHANGES OF PYRIMIDINE METABOLISM IN BLASTS OF 2 CASES OF ACUTE MYELOID-LEUKEMIA AFTER REPEATED TREATMENT WITH ARA-C INVIVO
    CHIBA, P
    TIHAN, T
    SZEKERES, T
    SALAMON, J
    KRAUPP, M
    EHER, R
    KOLLER, U
    KNAPP, W
    LEUKEMIA, 1990, 4 (11) : 761 - 765
  • [43] Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, B. Nebiyou
    Jabbour, Elias
    Ravandi, Farhad
    Yang, Hui
    Borthakur, Gautam
    Kadia, Tapan
    Cortes, Jorge
    Faderl, Stefan
    Konopleva, Marina
    Pierce, Sherry
    Burger, Jan A.
    Estrov, Zeev
    O'Brien, Susan
    Thomas, Deborah
    Newsome, Willie
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 436 - 436
  • [44] Troxatyl™ plus topotecan, ara-C, or idarubicin in patients (pts) with refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or blastic-phase chronic myeloid leukemia (CML-BP):: A randomized Phase I/II study.
    Giles, FJ
    Faderl, S
    Thomas, DA
    Cortes, J
    Jeha, SS
    Garcia-Manero, G
    Douer, D
    Levine, AM
    Estey, EH
    Beran, M
    O'Brien, S
    Koller, C
    Andreeff, M
    Kantarjian, H
    BLOOD, 2001, 98 (11) : 594A - 594A
  • [45] Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)
    A. Ganser
    G. Heil
    G. Seipelt
    W. Hofmann
    J. T. Fischer
    W. Langer
    W. Brockhaus
    K. Kolbe
    T. H. Ittel
    N. Brack
    H. G. Fuhr
    P. Knuth
    K. Höffken
    L. Bergmann
    D. Hoelzer
    Annals of Hematology, 2000, 79 : 30 - 35
  • [46] Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)
    Ganser, A
    Heil, G
    Seipelt, G
    Hofmann, W
    Fischer, JT
    Langer, W
    Brockhaus, W
    Kolbe, K
    Ittel, H
    Brack, N
    Fuhr, HG
    Knuth, P
    Höffken, K
    Bergmann, L
    Hoelzer, D
    ANNALS OF HEMATOLOGY, 2000, 79 (01) : 30 - 35
  • [47] Phase I/II pharmacodynamic study of the P-glycoprotein (Pgp) inhibitor zosuquidar administered by continuous infusion (CIV) with daunorubicin (DNR) and cytarabine (ARA-C) as primary therapy in older patients with acute myeloid leukemia (AML).
    Lancet, Jeffrey
    Baer, Maria R.
    Cripe, Larry D.
    List, Alan F.
    Marcelletti, John F.
    Multani, Pratik S.
    Sikic, Branimir I.
    BLOOD, 2006, 108 (11) : 129A - 129A
  • [48] Long-Term Follow-up of the Randomized JALSG AML 201 Study Comparing High Dose Ara-C Therapy with Conventional Consolidation Therapy in Adult Acute Myeloid Leukemia (AML)
    Miyawaki, Shuichi
    Ohtake, Shigeki
    Fujisawa, Shin
    Kiyoi, Hitoshi
    Shinagawa, Katsuji
    Usui, Noriko
    Miyamura, Kohichi
    Nishimura, Miki
    Miyazaki, Yasushi
    Nishii, Kazuhiro
    Nagai, Tadashi
    Yamane, Takahisa
    Taniwaki, Masafumi
    Takahashi, Masatomo
    Yagasaki, Fumiharu
    Kimura, Yukihiko
    Asou, Norio
    Honda, Sumihisa
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    BLOOD, 2008, 112 (11) : 56 - 56
  • [49] A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
    Tiong, Ing S.
    Loo, Sun
    Abro, Emad Uddin
    Hiwase, Devendra
    Fleming, Shaun
    Bajel, Ashish
    Palfreyman, Emma
    Fong, Chun Yew
    Teh, Tse-Chieh
    Ivey, Adam
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [50] A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
    Tiong, Ing S.
    Hiwase, Devendra
    Abro, Emad Uddin
    Bajel, Ashish
    Palfreyman, Emma
    Loo, Sun
    Fleming, Shaun
    Fong, Chun Yew
    Teh, Tse-Chieh
    Ivey, Adam
    Wei, Andrew H.
    BLOOD, 2022, 140 : 1453 - 1455
12345